RT Book, Section A1 Chahoud, Jad A1 Pettaway, Curtis A. A2 Kantarjian, Hagop M. A2 Wolff, Robert A. A2 Rieber, Alyssa G. SR Print(0) ID 1190837885 T1 Penile Cancer T2 The MD Anderson Manual of Medical Oncology, 4e YR 2022 FD 2022 PB McGraw Hill Education PP New York, NY SN 9781260467642 LK hemonc.mhmedical.com/content.aspx?aid=1190837885 RD 2024/10/04 AB KEY CONCEPTSHuman papillomavirus infection appears to be the possible cause of 30% to 50% of penile cancer cases and appears to have a prognostic impact on clinical outcomes among patients with advanced disease.Penile-preserving strategies should be strongly considered among patients with low-stage tumors, especially those limited to the skin and the distal glans penis.The presence and the extent of metastasis to the ­inguinal region are the most important prognostic factors for survival in patients with squamous cell carcinoma of the penis.Penile tumor T stage ≥ T1b, grade, lymphovascular invasion, and perineural invasion appear to be the most important pathologic prognostic factors for nodal spread. Their presence is used to determine the need for inguinal staging procedures among patients with no clinically apparent inguinal metastases.Patients with bulky lymphadenopathy should undergo a multimodal therapeutic approach to include neoadjuvant platinum-based chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) for four cycles followed by consolidation surgical lymph node dissection among responding patients.Patients with relapsed or refractory penile cancer to platinum-based chemotherapy have poor outcomes with current therapy modalities, and every effort should be made to enroll these patients on novel therapeutic clinical trials.